Physician profile
Bryan D Murphy
NPI 1619977519
$2,583.80
in general payments reported to CMS, 2019-2025
15 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $178 · 2021: $781 · 2022: $84.37 · 2023: $498 · 2024: $394 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.32 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $911.81 | 2021-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $496.32 | 2019-2025 | Dupixent |
| Stryker Corporation | $458.03 | 2019-2025 | Scopis Ent |
| Glaxosmithkline, LLC. | $174.47 | 2023-2025 | Nucala |
| Optinose US, INC. | $139.37 | 2019-2022 | |
| Integra Lifesciences Corporation | $76.77 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Smith+Nephew, INC. | $74.66 | 2023 | Tula |
| Medtronic, INC. | $62.62 | 2023-2025 | Pteye Parathyroid Detection System, Propel |
| Phathom Pharmaceuticals, INC. | $57.96 | 2024 | Voquezna |
| Genzyme Corporation | $32.78 | 2025 | |
| Cochlear Americas | $31.96 | 2020 | |
| Amgen INC. | $17.31 | 2025 | |
| Ethicon US, LLC | $17.07 | 2021 | |
| Intersect Ent, INC. | $16.42 | 2019 | |
| Boston Scientific Corporation | $16.25 | 2025 | Ingevity+ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.